HYB fib
Alternative Names: HYB-fibLatest Information Update: 03 Mar 2023
At a glance
- Originator Hybridize Therapeutics
- Class Anti-inflammatories; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Fibrosis
Most Recent Events
- 27 Dec 2022 Preclinical trials in Acute kidney injury in Netherlands (unspecified route) (Hybridize Therapeutics pipeline, December 2022)
- 27 Dec 2022 Preclinical trials in Fibrosis in Netherlands (unspecified route) (Hybridize Therapeutics pipeline, December 2022)